China SXT Pharmaceuticals (SXTC) Common Equity (2018 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Common Equity of $29.7 million for Q1 2026, up 92.41% year-over-year from $15.4 million in Q1 2025, and up 46.82% quarter-over-quarter from $20.2 million in Q3 2025.
China SXT Pharmaceuticals (SXTC) Common Equity (2018 - 2026) Analysis & Trends
China SXT Pharmaceuticals' Common Equity history runs 9 years deep, the most recent figure standing at $29.7 million for Q1 2026.
- In Q1 2026, Common Equity rose 92.41% year-over-year to $29.7 million; the TTM figure through Mar 2026 stood at $29.7 million (up 92.41% YoY), while the FY2026 annual figure was $29.7 million, up 92.41% from the prior year.
- Common Equity for Q1 2026 stood at $29.7 million, up from $20.2 million in the prior quarter.
- The five-year high for Common Equity was $29.7 million in Q1 2026, with the low at $5.1 million in Q3 2023.
- The 5-year median for Common Equity is $15.0 million (2024), against an average of $16.1 million.
- The sharpest annual moves came in 2023 and 2024: Common Equity sank 65.11% in 2023, then soared 196.18% in 2024.
- China SXT Pharmaceuticals' Common Equity stood at $14.5 million in 2022, then tumbled by 65.11% to $5.1 million in 2023, then jumped by 196.18% to $15.0 million in 2024, then jumped by 34.58% to $20.2 million in 2025, then soared by 46.82% to $29.7 million in 2026.
- Business Quant data shows SXTC's Common Equity at $29.7 million in Q1 2026, $20.2 million in Q3 2025, and $15.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | China SXT Pharmaceuticals | 32,922.00 | -28.14 Mn | - | 29.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.71 Mn |
| Sep 30, 2025 | 20.23 Mn |
| Mar 31, 2025 | 15.44 Mn |
| Sep 30, 2024 | 15.03 Mn |
| Mar 31, 2024 | 13.93 Mn |
| Sep 30, 2023 | 5.08 Mn |
| Mar 31, 2023 | 14.69 Mn |
| Sep 30, 2022 | 14.55 Mn |
| Mar 31, 2022 | 16.08 Mn |
| Sep 30, 2021 | 13.79 Mn |
| Mar 31, 2021 | 15.96 Mn |
| Sep 30, 2020 | 18.52 Mn |
| Mar 31, 2020 | 9.40 Mn |
| Sep 30, 2019 | 11.41 Mn |
| Mar 31, 2019 | 11.11 Mn |
| Sep 30, 2018 | 4.60 Mn |
| Mar 31, 2018 | 3.29 Mn |